Hydronephrosis Market Research Report - Global Forecast Till 2027

Hydronephrosis Market Information: By Type (Unilateral, Bilateral), By Diagnosis (Laboratory Tests, Imaging), By Treatment (Shock Wave Lithotripsy, Laparoscopy, Bladder Catheterization, Steroid Therapy, Others), And By Indication (Intrinsic, Extrinsic) - Global Forecast Till 2027

ID: MRFR/Pharma/2879-HCR | February 2021 | Region: Global | 206 pages

Please note that the assessment period of report has been updated from 2023 to 2027. Cordially fill the sample form for updated data.

Market Synopsis of the Global Hydronephrosis Market Market Scenario Hydronephrosis is a condition characterized by a swollen kidney as a result of abnormal drainage of urine from the kidney to the bladder. It is a secondary disease that results from primary disease that may affect the kidney. Symptoms of hydronephrosis includes fever, pain when urinating, nausea or vomiting, and pain in the abdomen. It may be unilateral or bilateral. Unilateral hydronephrosis is swelling  of one kidney, whereas, bilateral hydronephrosis is swelling of both the kidneys. Hydronephrosis is mostly diagnosed through ultrasound examination.


Hydronephrosis has become a major problem across the globe due to rising prevalence of kidney diseases, lack of awareness about the diseases and their treatment, which favor the growth of the market. Rising prevalence of kidney diseases especially, in the geriatric population and availability of cost-effective treatment propel the market growth.


The global hydronephrosis market is expected to grow at a CAGR of 10.2% during the forecast period and is estimated to reach USD 250 million by 2023.


FIGURE 1 Global Hydronephrosis Market by Diagnosis, 2016 (%) Hydronephrosis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation Key Players in the Global Hydronephrosis Market                                         Some of the key players in this market are NephroGenex, Inc. (U.S), American Renal Associates (U.S), PHRAXIS, INC. (U.S), Renal Associates P.A. (U.S), ALLERGAN (U.S), Amgen Inc. (U.S), Anthem Bio Pharm (U.S), Sanofi (U.S), and Novartis AG (Germany)   .


Segments The global hydronephrosis market is segmented on the basis of types, which includes unilateral hydronephrosis and bilateral hydronephrosis.


On the basis of diagnosis, the market is segmented into laboratory test and imaging. Laboratory test is further segmented into urinalysis, Complete Blood Count (CBC), electrolyte analysis, and others. Imaging is further sub-segmented into CT scan, ultrasound, intravenous pyelography, KUB X-rays, and others.


On the basis of treatment, the market is segmented into shock wave lithotripsy, laparoscopy, bladder catheterization, steroid therapy, and others.


On the basis of indication the market is segmented into intrinsic and extrinsic causes of hydronephrosis. The intrinsic causes are further sub-segmented into acute unilateral obstructive uropathy, kidney stone, bladder cancer, bladder stones, cystocele, urethral stricture, urethral cancer and others. The extrinsic causes are further sub-segmented into retroperitoneal fibrosis, ovarian vein syndrome, cancer of the cervix, cancer of the prostate, uterine prolapse, prostate cancer, and others.


Research Methodology Hydronephrosis Market-


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 


 


Regional Analysis of the Global Hydronephrosis Market             The American region accounted for the largest share of the global market due to increasing prevalence of chronic kidney diseases, and rising demand for diagnosis and treatment of hydronephrosis. Hydronephrosis are leading urological diseases in the U.S. According to the Center for Diseases Control and Prevention, 48,146 deaths occurred due to nephrosis and kidney diseases in the year 2014. It also stated that the number of adults diagnosed with kidney diseases in 2014 was 4.9 million in the US.


Europe is the second largest market that holds a noticeable share of the global hydronephrosis market. According to the European database for surveillance of congenital malformations report, hydronephrosis is prevalence among new born and pregnant women.


In Asia Pacific, rising prevalence of kidney stone, rising geriatric population and growing demand for counselling about hydronephrosis drive the market growth. 


The Middle East & Africa is expected to show a steady growth in this market due constant demand for diagnostics devices, awareness about maternal and child health in most of the African countries and the government efforts to cater primary health need of the population.The report on the global hydronephrosis market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Intended Audience



  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 



Frequently Asked Questions (FAQ) :


Hydronephrosis market is projected to grow at a 10.2% CAGR between 2017- 2023.

The Americas is expected to dominate the hydronephrosis market.

Hydronephrosis market is predicted to touch USD 250 million by 2023.

Rising prevalence of kidney disease and availability of cost-effective treatment are the key factors driving the hydronephrosis market.

Notable players profiled in the hydronephrosis market include Novartis AG (Germany), Sanofi (U.S), Anthem Bio Pharm (U.S), Amgen Inc. (U.S), ALLERGAN (U.S), Renal Associates P.A. (U.S), PHRAXIS, INC. (U.S), American Renal Associates (U.S), and NephroGenex, Inc. (U.S).

Brief TOC
1 Report Prologue
2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations
3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation
4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment
5. Market Factor Analysis

5.1 Porters five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain

5.3 Investment Feasibility Analysis

5.4 Price Factor Analysis
6 Global Hydronephrosis Market, by Type

6.1 Introduction

6.2 Unilateral Hydronephrosis

6.3 Bilateral Hydronephrosis
7 Global Hydronephrosis Market, by Diagnosis

7.1 Introduction

7.2 Laboratory Test

7.2.1 Urinalysis

7.2.2 Complete Blood Count

7.2.3 Electrolyte Analysis

7.2.4 Others

7.3 Imaging

7.3.1 CT Scan

7.3.2 Ultrasound

7.3.3 Intravenous Pyelography

7.3.4 KUB X-Rays

7.3.5 Others
8 Global Hydronephrosis Market, by Treatment

8.1 Introduction

8.2 Shock Wave Lithotripsy

8.3 Laparoscopy

8.4 Bladder Catheterization

8.5 Steroid Therapy

8.6 Others
9 Global Hydronephrosis Market by Indication

9.1 Introduction

9.2 Intrinsic

9.2.1 Acute Unilateral Obstructive Uropathy

9.2.2 Kidney Stone

9.2.3 Bladder Cancer

9.2.4 Bladder Stones

9.2.5 Cystocele

9.2.6 Urethral Stricture

9.2.7 Urethral Cancer

9.2.8 Others

9.3 Extrinsic

9.3.1 Retroperitoneal Fibrosis

9.3.2 Ovarian Vein Syndrome

9.3.3 Cancer of the Cervix

9.3.4 Cancer of the Prostate

9.3.5 Uterine Prolapse

9.3.6 Prostate Cancer

9.3.7 Pregnancy

9.3.8 Others
10 Global Hydronephrosis Market by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Republic of Korea

10.4.5 Australia

10.4.6 Rest of Asia Pacific

10.5 Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of Middle East & Africa
11 Company Landscape

11.1 Introduction

11.2 Market share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments
12 Company Profiles

12.1 NephroGenex, Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 American Renal Associates

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 PHRAXIS, INC.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Renal Associates P.A.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 ALLERGAN

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Amgen Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Novartis AG

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis
13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Healthcare Industry
14 Appendix